From Site of Care Migration to the Impact of Reimbursement Changes SmartTRAK evaluates market trends to watch for in 2022.
by Gary Delhougne, GM Wound

The Skin Substitute/CTP (Cellular and/or Tissue-based Products) market is undergoing significant growth and change. Reimbursement motives, COVID-19 and clinician site of care decisions had a profound impact on the market in 2020 and 2021. The growth outlook for 2022 remains strong as providers and industry adapt to unique market conditions.

SmartTRAK estimates the 5-year CAGR (compound annual growth rate) through 2025 for Skin Substitutes/CTP products to be in the mid to high single digits. In 2020, industry revenue surpassed $1B and SmartTRAK expects the market to pass $1.5B by 2025.

To better understand the impact of site of care changes, SmartTRAK launched a new subscription module specifically covering site of care changes occurring in the Skin Substitute/CTP market. It’s SmartTRAK’s fastest-growing new product offering and you can learn more by clicking here.

As SmartTRAK looks to 2022, we see three trends to consider for the Skin Substitute/CTP market –